Tirzepatide improves glucose control by enhancing insulin secretion and (mostly) suppressing glucagon release, helping to lower blood sugar levels
doi: 10.1152/physrev.00034.2006 2 Inflammation
Clinical Pearl: Ideal Candidates for Combination Therapy Patients that will greatly benefit from L-carnitine adjunctive therapy: Report persistent fatigue despite adequate weight loss on GLP-1 therapy alone Demonstrate signs of muscle loss or declining lean body mass during treatment Have plateaued in their weight loss despite medication optimization Present with metabolic syndrome features beyond elevated BMI (dyslipidemia, insulin resistance) Engage in regular physical activity and seek enhanced athletic performance alongside weight management Monitoring Parameters Regular assessment should include: Weight and body composition measurements every 4-6 weeks Lipid panel and HbA1c at 3-month intervals Liver function tests at baseline and 6 months (L-carnitine may affect hepatic fat metabolism) Patient-reported outcomes: energy levels, GI tolerability, exercise capacity Prescribing Patterns & Updates Growing Interest in Combination Metabolic Therapies Clinical practice patterns indicate increasing adoption of adjunctive therapies alongside GLP-1 medications
FOLLOW US FOR GIVEAWAYS, SPECIAL OFFERS & ADDITIONAL INFORMATION ON OUR PRODUCTS.
TB-500: Often paired with BPC-157 to support injury recovery, mobility, and training longevity
It is not the first time the TGA has issued such a warning, with the viral weight-loss drugs popularity showing no signs of slowing down
